Psychedelic-assisted therapy has been one of the most-covered mental-health stories of the past decade. A 2026 quantitative analysis by Evers and colleagues maps how media enthusiasm grew, peaked, and partially pulled back across major U.S. outlets — and how the coverage related to the actual evidence base for depression and PTSD.1 Research Highlights Psychedelic clinical …
PTSD and major depressive disorder co-occur in roughly half of patients with either diagnosis, and the comorbid presentation is more severe than either alone. The mechanistic question has been whether comorbidity reflects synergistic biology or simple symptom additivity. A 2026 rat-model study by Jiang and colleagues tests this directly, finding that PTSD-MDD comorbid rats show …
SSRIs raise bleeding risk on their own. DOACs (direct oral anticoagulants — apixaban, rivaroxaban, dabigatran, edoxaban) raise it more. The intuitive worry is that combining them stacks the two effects. A new BJGP Open analysis from Chau and colleagues argues the stacking is smaller than most popular framings claim, and that the real safety question …
Deep Brain Stimulation (DBS) for Treatment-Resistant Depression (TRD) explores the cutting-edge intersection of technology and neuroscience, offering hope to those for whom traditional treatments have failed. By targeting specific brain areas, such as the nucleus accumbens, DBS attempts to modulate the underlying neural circuits associated with depression. A recent review analyzed case reports documenting significant …
Tramadol, commonly known for its pain-relieving properties, has emerged as an effective off-label treatment for depression according to patient experiences and reviews. A recent analysis of tramadol’s antidepressant potential examined user feedback – comparing its efficacy and safety with established antidepressants. It considered the perspectives of patients who have found relief from depression with tramadol, …
The intersection of mental health treatment and pharmacology is witnessing a remarkable shift with the growing interest in ketamine and classic psychedelics like psilocybin for their rapid and sustained antidepressant effects. Unlike traditional antidepressants, these substances offer hope for those with treatment-resistant depression by potentially transforming treatment paradigms. However, it remains somewhat unclear as to …
Tianeptine is an atypical antidepressant that has been approved in several countries for treating depression but is not authorized for medical use in the United States. Despite this, it has found a significant market in the U.S. as a nootropic, often sold under names like ZaZa or Tianna Red, and has been nicknamed “gas station …